Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.51 |
| ▸ | FYN | P06241 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 7/20 | 0.51 |
| ▸ | CA12 | O43570 | 6/20 | 0.50 |
| ▸ | CA1 | P00915 | 6/20 | 0.50 |
| ▸ | CA9 | Q16790 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.47 |
| ▸ | CA5A | P35218 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1776767 | 1.00 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10TSHRNR3C1 | |
| SCHEMBL7565739 | 1.00 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10TSHRNR3C1 | |
| SCHEMBL6788287 | 1.00 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10TSHRNR3C1 | |
| SCHEMBL130217 | 1.00 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10TSHRNR3C1 | |
| SCHEMBL12281867 | 1.00 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10TSHRNR3C1 | |
| SCHEMBL25083758 | 1.00 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10TSHRNR3C1 | |
| SCHEMBL6788279 | 1.00 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10TSHRNR3C1 | |
| SCHEMBL12237522 | 1.00 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10TSHRNR3C1 | |
| SCHEMBL19861473 | 1.00 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10TSHRNR3C1 | |
| SCHEMBL16215761 | 1.00 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10TSHRNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970353-B1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMA (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9890176-B2 | Mannose derivatives for treating bacterial infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-02-13 | — | — | US | disclosed |
| EP-2970353-A2 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014165107-A2 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140274930-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-18 | — | — | US | disclosed |
| US-5770407-A | Process for preparing nucleotide inhibitors of glycosyltransferases | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140274930-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | TLR5, TLR1, MANBA | CYP2D6 2933/4885THRB 3734/4885HSD17B10 3342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.